PHREESIA INC (PHR)
Health Care · Healthcare Technology (HealthTech) · NYSE
Phreesia offers an integrated patient intake, engagement, and payment platform that digitizes the healthcare experience for providers and patients.
What PHREESIA INC does
Phreesia provides an integrated software, payments, and engagement platform that helps healthcare organizations streamline patient intake, administrative processes, and financial workflows. The company's solutions support the patient journey from care discovery and scheduling through intake, payment, and post-visit follow-up, aiming to improve access to care, affordability, and health outcomes. Phreesia serves a diverse client base including ambulatory practices, health systems, hospitals, and life sciences companies.
Recent developments
Phreesia implemented a restructuring plan in May 2026 to reduce operating expenses and align its cost structure, which involved the elimination of approximately 220 positions. The company also completed the acquisition of AccessOne to expand its healthcare payment and financing market share. In its Q2 FY2027 earnings, the company maintained its full-year revenue outlook of $510-$520 million.
From PHREESIA INC's filing of 2026-09-03.
Themes: patient engagement, digital health workflow automation, healthcare payments / revenue cycle management, AI in healthcare administration, telehealth / patient access, life sciences marketing and analytics
Fundamentals
- Price$12.26 as of 2026-10-21 close
- Market cap$761M as of 2026-08-27 (share count; price 2026-10-21)
- 1-year return-46.9% 2025-10-21 close $23.11 → 2026-10-21 close $12.26
- P/E68.11 as of 2026-10-21
- Net margin+0.5% FY2026, SEC XBRL
- ROE+0.7% FY2026, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its interest expense implies more borrowing than the debt lines we read add up to.
- Revenue growth (YoY)+14.5% FY2026, SEC XBRL
- Revenue CAGR (3y)+19.6% SEC XBRL
- Beta0.86 as of 2026-09-02
- Last reported earnings2026-09-02 SEC EDGAR Form 8-K (Item 2.02)
How PHR compares in its sector
- price-to-earnings ratiotop 25% 181 covered Health Care peers, as of 2026-10-21
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2027 2026-07-31 | $129M | $8M | $2M | $0.03 | $18M | $492000 |
| Q1 FY2027 2026-04-30 | $131M | $7M | $3M | $0.05 | $24M | $4M |
| Q4 FY2026 2026-01-31 | $127M† | -$6M† | $1M† | $0.02† | $34M† | $3M† |
| Q3 FY2026 2025-10-31 | $120M | $4M | $4M | $0.07 | $15M | $3M |
| Q2 FY2026 2025-07-31 | $117M | -$2M | $654000 | $0.01 | $15M | $2M |
| Q1 FY2026 2025-04-30 | $116M | -$3M | -$4M | -$0.07 | $15M | $4M |
| Q4 FY2025 2025-01-31 | $110M† | -$8M† | -$6M† | -$0.11† | $16M† | $3M† |
| Q3 FY2025 2024-10-31 | $107M | -$14M | -$14M | -$0.25 | $6M | $616000 |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-07-31
- Cash and equivalents$75M includes restricted cash (the filer tags no unrestricted total)
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How PHREESIA INC looks technically
PHREESIA INC (PHR) is trading 8.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 253 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend). Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-08-14, pushing above its recent trading range. It is 49.1% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 8.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +8.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.97 | $10.97 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $11.27 | $11.27 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 54 calendar days ago — the swings before that are what the structure reading is measured on | 54 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 12.29. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 253 trading days ago — a "death cross", a bearish long-term signal | 253 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 8.8% above | +8.8% |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 24 (a reading of 25+ marks a strong trend) | 23.7 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 73, in overbought territory (above 70) | 73.0 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($10.06 to $12.54) — its "stochastic" reading is 89 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 88.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 16 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $24.07 | $24.07 |
|---|---|---|
| From the 52-week high | it is 49.1% below its 52-week high (its highest price of the past year) | -49.1% |
| Above the 52-week low | it is 57.8% above its 52-week low (its lowest price of the past year) | +57.8% |
| Below the 52-week high | it is 49.1% below its highest point of the past year | 49.1% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-08-14, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day low about 21 trading days ago | 21 sessions |
| All-time high | its highest closing price on record is $81.59 (set on 2021-02-10) | $81.59 |
| Given back of the 52-week move | over the past year its closes ranged ($8.06 to $23.49), and it has recovered roughly a quarter of its fall from last year’s high — 27% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.60 to $18.09. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 27.2% |
| From the all-time high | it is 85.0% below its all-time high | -85.0% |
| Nearest price level | it is trading 0.5% below a resistance level at $12.32 — a price it turned at twice since 2026-03-20, most recently on 2026-08-28. Since 2024-10-21 it has 4 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.5% |
| All-time low | its lowest closing price on record is $7.77 (set on 2026-03-31) | $7.77 |
| Above the all-time low | it is 57.8% above its all-time low | +57.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 64th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4351 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4351 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $9.45 and $11.89 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $9.45 – $10.67 – $11.89 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.5% |
| Stretch from the 200-day average | it is trading 2.3 daily ranges above its 200-day average price (8.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.48× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.5% since the prior reading | +0.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 3.0% gap down opened on 2026-10-12 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +12.07% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 22.3 percentage points (the stock gained 22.2% while the market lost 0.1%) | +22.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 12.3 percentage points (the stock gained 15.7% while the market gained 3.3%) | +12.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 21.2 percentage points (the stock gained 31.0% while the market gained 9.8%) | +21.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 62.1 percentage points (the stock lost 46.9% while the market gained 15.2%) | -62.1% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.1% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.9% of the share price, which is taken to mean a barrier that gives way easily. | +8.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 12% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.90 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +12.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% above the average price paid since it last reported on 2026-09-02 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $10.60 — a volume-weighted average of daily closes over 35 sessions, not a true tick-by-tick VWAP. | +15.6% |
Price levels it has turned at before
PHR last closed at $12.26 on 2026-10-21. Since 2024-10-21 it has turned at 4 prices below its last close and 13 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $12.32 | Resistance | 0.5% above the last close | turned there twice · 2026-03-20 to 2026-08-28 |
| $12.90 | Resistance | 5.3% above the last close | turned there three times · 2026-02-20 to 2026-08-07 |
| $11.52 | Support | 6.0% below the last close | turned there twice · 2026-02-12 to 2026-07-07 |
| $11.29 | Support | 8.0% below the last close | turned there twice · 2026-02-25 to 2026-08-19 |
| $10.27 | Support | 16.2% below the last close | turned there twice · 2026-05-08 to 2026-07-09 |
| $17.67 | Resistance | 44.1% above the last close | turned there twice · 2024-10-29 to 2026-01-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $12.29.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 33 trading days, since 2026-09-04.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Broke out to a new 20-day high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.00 mean, 1=Strong Buy…5=Strong Sell) — 15 analysts
- Mean price target$14.13 range $10.00 – $20.00; median $14.00
Analyst estimates, as of 2026-10-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PHR
- Consensus EPS estimate$0.3659 next reporting period, as of 2026-10-18
- Estimate change, 30 days+$0.0077 (+2.1%) from $0.3582, on 2026-09-13, 35-day window
- Readings revised upward20% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intense competition from EHR/PM system providers and other health-tech entrants.","Risks associated with developing and integrating new technologies and AI-enabled services.","Potential for variability in Network Solutions revenue based on life sciences marketing budgets."]
What changed in the latest 10-Q
AI-assisted comparison of PHR's 10-Q filed 2026-05-28 against the prior one filed 2025-12-09.
Management's Discussion & Analysis (MD&A)
- Added:
- New filing includes AccessOne as part of consolidated entity for periods on or after November 12, 2025 (newer filing filed 2026-05-28)
- Financial highlights for three months ended April 30, 2026: Total revenue $130.9 million (13% increase), Net income $3.0 million, Adjusted EBITDA $30.5 million, Operating cash flow $23.9 million, Free cash flow $16.4 million
- Cash and cash equivalents as of April 30, 2026 was $76.4 million, an increase of $2.6 million compared to January 31, 2026, with $1.7 million of long-term restricted cash included
- Statement that platform facilitated approximately 180 million patient visits in fiscal year 2026, representing approximately one in six ambulatory patient visits in the United States
- Three core areas framework: Access, Affordability, and Outcomes with detailed capability descriptions for each
- Description of diversified revenue model with three streams: subscription and related services, payment solutions, and Network Solutions
- Explanation of revenue seasonality patterns for each revenue stream
- Reference to fiscal year 2026 Form 10-K filed March 31, 2026
- Removed:
- Financial highlights for three months ended October 31, 2025: Total revenue $120.3 million (13% increase), Net income $4.3 million, Adjusted EBITDA $29.1 million, Operating cash flow $15.5 million, Free cash flow $8.8 million (older filing filed 2025-12-09)
- Nine months ended October 31, 2025 financial metrics entirely removed
- Cash and cash equivalents as of October 31, 2025 was $106.4 million, an increase of $22.2 million compared to January 31, 2025
- Detailed description of AccessOne acquisition as a separate event with note that subsequent results not included in discussion (older filing treated it as post-period event)
- Original overview description characterizing Phreesia as 'leading provider of comprehensive software solutions' with detailed product listing
- Specific mention of clinical assessments to screen patients for physical, behavioral and mental health conditions
- Detailed description of revenue derivation from four sources (subscription fees, payment processing fees, life sciences fees, and MediFind)
- Reference to fiscal year 2025 Form 10-K filed March 13, 2025
- Reworded:
- Overview section reframed from describing Phreesia's mission to 'make care easier every day' to describing an 'integrated software, payments, and engagement platform' addressing three foundational challenges
- Changed from 'comprehensive software solutions that improve operational and financial performance' to 'integrated software, payments, and engagement platform designed to address three foundational challenges'
- Description of served organizations changed from 'healthcare services clients of all sizes across over 25 specialties' to 'diverse group of healthcare organizations including ambulatory practices, health systems, and hospitals'
- Risk factors reference changed from 'under "Risk Factors"' to 'in the "Risk Factors" and "Special Note Regarding Forward-Looking Statements": section'
- Typo correction: 'follow discussion' changed to 'following discussion' in older filing's forward-looking statements disclaimer
- Notes:
- Older filing text appears truncated at end of Overview section; comparison based on available text
- Newer filing also appears truncated at end of Overview section; full scope of changes may not be fully captured
- Different fiscal periods being compared: newer filing covers three months ended April 30, 2026 while older filing covers three months ended October 31, 2025 and nine months ended October 31, 2025
Risk Factors
- Added:
- Added phrase 'solutions and services' instead of just 'products and services' in opening paragraph of first risk factor (2026-05-28 filing)
- Added 'or on terms less favorable to us' regarding client contract renegotiation in first risk factor (2026-05-28 filing)
- Added 'clients' operations and' before 'patient engagement' in discussion of streamlining workflows (2026-05-28 filing)
- Added 'unfavorably' as modifier when discussing contract renegotiation in competitive factors section (2026-05-28 filing)
- Changed 'our services' to 'our solutions' in competitive comparison section (2026-05-28 filing)
- Removed:
- Removed 'the intake process and' from the phrase about streamlining workflows in demand discussion (2025-12-09 filing had this language)
- Removed 'healthcare services organization, staff efficiency and' and replaced with 'healthcare services clients'' in workflow streamlining discussion (2025-12-09 filing had more detailed phrasing)
- Reworded:
- Changed 'The market for our products and services' to 'The market for our solutions and services' in opening of competitive landscape paragraph (2026-05-28 vs 2025-12-09)
- Changed 'developing new products and services' to 'developing new solutions and services' when discussing industry standards adaptation (2026-05-28 vs 2025-12-09)
- Changed 'We believe demand for our products and services' to 'We believe demand for our solutions and services' (2026-05-28 vs 2025-12-09)
- Changed 'even if our services are more effective' to 'even if our solutions are more effective' in competitive comparison (2026-05-28 vs 2025-12-09)
- Changed 'the market for our products and services' to 'the market for our products and services' - no substantive change but document references 'solutions' more broadly (2026-05-28 vs 2025-12-09)
- Notes:
- Both filings appear truncated at the end (cut off at 'strain on our busines'), so full comparison of growth management section not possible
- Terminology shift from 'products and services' to 'solutions and services' appears systematic throughout the newer filing, suggesting possible rebranding or terminology standardization rather than substantive business changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 5 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-170 buys · 1 sell ($67153) — 1 selling insider
- Last 180 days · read to 2026-10-170 buys · 6 sells ($129445) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-21. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PHR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for PHR from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding PHR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 10,183,273
- Reported value $104,785,880
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about PHR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
PHR had 3,015,320 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
PHR had 4.86% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.94 days to cover at the same settlement.
- Reported short interest (shares) 3,015,320
- Short interest (% of shares outstanding) 4.86%
- Prior settlement (shares) 3,114,156
- Reported change -3.17%
- Days to cover (reported) 3.94
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Epic Systems
- Cerner (Oracle)
- Athenahealth
- NextGen Healthcare
- Waystar Technologies
- Change Healthcare (UnitedHealth)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PHR vs…
Frequently asked questions
What does PHREESIA INC (PHR) do?
Phreesia provides an integrated software, payments, and engagement platform that helps healthcare organizations streamline patient intake, administrative processes, and financial workflows. The company's solutions support the patient journey from care discovery and scheduling through intake, payment, and post-visit follow-up, aiming to improve access to care, affordability, and health outcomes.
What sector is PHREESIA INC (PHR) in?
PHREESIA INC (PHR) is classified in the Health Care sector. Its industry is Healthcare Technology (HealthTech). It trades on NYSE.
Who are PHREESIA INC's (PHR) competitors?
Notable peers of PHREESIA INC (PHR) include Epic Systems, Cerner (Oracle), Athenahealth, NextGen Healthcare and Waystar Technologies. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in PHR?
Yes — we hold 4 matched STOCK Act disclosures for PHR from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is PHREESIA INC (PHR) overbought or oversold right now?
PHREESIA INC (PHR) is currently in overbought territory (its 14-day RSI is 73, above 70) (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PHR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.